Kailera Therapeutics director files Form 3

Kailera Therapeutics, Inc. director Liu Yuting filed an initial Form 3, which is a statement of beneficial ownership by an insider.

Accepted by SEC EDGAR 04/16/2026 - 07:40 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kailera Therapeutics, Inc. director Liu Yuting filed an initial Form 3, which is a statement of beneficial ownership by an insider. The filing shows no reported transactions, no derivative positions, and no buy, sell, acquire, or dispose activity in the securities of Kailera Therapeutics at this time.

Key Terms

Form 3, reporting person, director

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [ { "name": "Liu Yuting""

director financial

""is_director": 1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filed for Kailera Therapeutics (KLRA) show?

The Form 3 for Kailera Therapeutics (KLRA) identifies Liu Yuting as a company director and reporting person. It reports no transactions, no derivative holdings, and no buy, sell, acquire, or dispose activity in KLRA securities as of the filing’s disclosure snapshot.

Who is the reporting person on the Kailera Therapeutics (KLRA) Form 3?

The reporting person is Liu Yuting, identified as a director of Kailera Therapeutics, Inc. The filing indicates no officer role, no ten percent owner status, and provides no reported transactions or derivative security positions associated with this insider at the time reported.

Does the KLRA Form 3 show any insider buying or selling of shares?

No. The KLRA Form 3 transaction summary shows zero buy, sell, acquire, or dispose events and zero reported shares for each category. It also indicates no exercises, gifts, tax withholding events, or restructuring-related transfers during the period covered.

Are there any derivative securities reported for Liu Yuting in KLRA?

No derivative securities are reported. The Form 3 lists an empty derivativeSummary and a derivativeTransactionCount of zero. This means there are no disclosed options, warrants, or other derivative positions associated with Liu Yuting in Kailera Therapeutics at the disclosure point.

What does the netBuySellDirection field indicate in the KLRA Form 3?

The Form 3 shows a netBuySellDirection of "neutral" with netBuySellShares at zero. This reflects that there were no net purchases or sales, consistent with the absence of any reported transactions or share movements for the reporting person in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Liu Yuting

(Last) (First) (Middle)

C/O KAILERA THERAPEUTICS, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/16/2026

3. Issuer Name and Ticker or Trading Symbol
Kailera Therapeutics, Inc. [ KLRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ John Mei, Attorney-in-fact	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)